Norfloxacin Treatment of Salmonellosis Does Not Shorten the Carrier Stage
- 1 January 1990
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 22 (5) , 553-556
- https://doi.org/10.3109/00365549009027095
Abstract
In a prospective controlled study we evaluated the effect of early norfloxacin treatment on the duration of salmonella carriage after acute salmonellosis. The study was carried out during an outbreak of Salmonella typhimurium infection at a military base. 23 patients received norfloxacin 400 mg twice daily for 7 days while 29 patients served as untreated controls. A patient was considered to have ceased being a carrier on the date of the first of 3 negative consecutive cultures. Four weeks after diagnosis 30% of the treated patients and 31% in the control group were still carriers. The corresponding figures after 8 and 12 weeks were 17 and 3% and 4 and 0%, respectively. Thus, one week of norfloxacta treatment instituted at an early stage of salmonellosis did not shorten the duration of carriage.This publication has 7 references indexed in Scilit:
- CiprofloxacinDrugs, 1988
- A Review of Human Salmonellosis: III. Magnitude of Salmonella Infection in the United StatesClinical Infectious Diseases, 1988
- Spontaneous relapse of naproxen-related nephrotic syndromeThe American Journal of Medicine, 1987
- Problems in Salmonellosis: Rationale for Clinical Trials with Newer -Lactam Agents and QuinolonesClinical Infectious Diseases, 1986
- A controlled trial comparing sulfamethoxazole-trimethoprim, ampicillin, and no therapy in the treatment of salmonella gastroenteritis in childrenThe Journal of Pediatrics, 1973
- Treatment of Acute Gases of Salmonella Infection and Salmonella Carriers with Ampicillin and NeomycinActa Medica Scandinavica, 1964